Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oxford BioDynamics PLC (GB:OBD)
LSE:OBD
Holding GB:OBD?
Track your performance easily
OBD Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range3.40p - 52.00p
Previous Close3.45p
Volume1.06M
Average Volume (3M)1.01M
Market Cap
£10.76M
Enterprise Value11.95M
Total Cash (Recent Filing)£5.25M
Total Debt (Recent Filing)£6.44M
Price to Earnings (P/E)―
Beta-0.97
Next Earnings
Jan 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding311,860,000
10 Day Avg. Volume3,906,747
30 Day Avg. Volume1,008,127
Standard Deviation0.37
R-Squared0.03
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)21.10
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oxford BioDynamics News
PremiumCompany Announcements
Oxford BioDynamics Reports Shift in Major HoldingsPremiumCompany Announcements
Oxford BioDynamics Reports Major Shareholding Change
PremiumCompany Announcements
Oxford BioDynamics Shareholding Structure ShiftsPremiumCompany Announcements
Oxford BioDynamics Unveils EpiSwitch at Biomarker Summit
PremiumCompany Announcements
Oxford BioDynamics Rewards Staff with Share Options
PremiumCompany Announcements
Oxford BioDynamics Advances with EpiSwitch Growth
PremiumCompany Announcements
Oxford BioDynamics’ Test Joins Major Cancer Trial
PremiumCompany Announcements
Innovative Canine Cancer Blood Test UnveiledOptions Prices
Currently, No data available
---
Ownership Overview
18.47% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
81.53% Public Companies and
Individual Investors
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 3.40p and its highest was 52.00p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Currently, no data Available
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 28, 2025 which is in 130 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Oxford BioDynamics PLC released its earnings results on Jun 18, 2024. The company reported -0.023p earnings per share for the quarter, missing the consensus estimate of N/A by -0.023p.
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 311,855,650 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Oxford BioDynamics PLC reported an EPS of -0.023p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.896%.
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
---
Oxford BioDynamics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.12%
12-Months-Change
Fundamentals
Return on Equity
-266.70%
Trailing 12-Months
Asset Growth
-22.52%
Trailing 12-Months
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. The firm provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development.
---
Technical Analysis
---